TRxADE HEALTH, Inc. announced that it has entered into a Securities Purchase Agreement with new investor, Hudson Global Ventures, LLC to issue 290 shares of the Company?s Series C Convertible Preferred Stock at a price of $1,000 per share, convertible into shares of the Company?s common stock, par value $0.00001 per share and a warrant to purchase up to 41,193 shares of Common Stock for the aggregate gross proceeds of $290,000 on October 4, 2023. The warrant is immediately exercisable subject to certain beneficial ownership limitations, has an exercise price of $7.20 per share, and will expire on the fifth anniversary of its issue date. Each share of Series C Preferred Stock shall be convertible, at any time and from time to time, at the option of the holder, into that number of shares of common stock, subject to certain beneficial ownership limitations, determined by dividing the stated value of such share of Series C Preferred Stock by the conversion price.

The Securities are being sold pursuant to an exemption from registration under the Securities Act of 1933, as amended, available under Section 4(a)(2) and Rule 506(b) of Regulation D promulgated thereunder.